2019
DOI: 10.1111/dth.13029
|View full text |Cite
|
Sign up to set email alerts
|

The influence of ustekinumab on expression of STAT1 , STAT3 , STAT4 , SOCS2 , and IL17 in patients with psoriasis and in a control

Abstract: The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 31 publications
0
3
0
1
Order By: Relevance
“…Moreover, these mice also failed to develop psoriasis-like inflammation suggesting the essential role of STAT3 in the production of inflammatory cytokines and development of psoriatic lesions [85]. The key role of STAT3 in the development of psoriatic lesion is further supported by a study showing that treatment with ustekinumab (a monoclonal antibody that targets IL-12 and IL-23 and is used clinically for psoriasis) down-regulates the expression of STAT3 in psoriatic patients [86].…”
Section: Il-17 Nf-kb and Signal Transducer And Activator Of Transcrmentioning
confidence: 95%
“…Moreover, these mice also failed to develop psoriasis-like inflammation suggesting the essential role of STAT3 in the production of inflammatory cytokines and development of psoriatic lesions [85]. The key role of STAT3 in the development of psoriatic lesion is further supported by a study showing that treatment with ustekinumab (a monoclonal antibody that targets IL-12 and IL-23 and is used clinically for psoriasis) down-regulates the expression of STAT3 in psoriatic patients [86].…”
Section: Il-17 Nf-kb and Signal Transducer And Activator Of Transcrmentioning
confidence: 95%
“…STAT1 and STAT3 are critical transcription regulatory factors that control cell growth, programmed cell death pathways, and in ammatory responses. The expression levels of STAT1 and STAT3 are higher in patients with psoriasis vulgaris compared to healthy individuals 33 . The balanced regulation between STAT3 and STAT1 controls the expression of IL-22 and IL-17A, in uencing skin in ammation 34 .…”
Section: Discussionmentioning
confidence: 91%
“…For instance, STAT1, a transcription hub, inhibits the expression of metalloproteinases-3, influencing the cell adhesion molecule pathway and blood vessel formation [ 44 ]. STAT1 also affects the activity of the IL-22 promoter, which plays an important role in tissue repair and inflammatory responses [ 45 , 46 ]. ZFX acts as an important regulator in the proliferation and migration of keratinocytes in skin wound healing.…”
Section: Resultsmentioning
confidence: 99%